Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
THE Mining Investment Event 2026 Announces Keynote Speakers and Panels, Additional Sponsors and Participating Companies
Kobo Resources Announces Closing of Non-Brokered Private Placement for Gross Proceeds of $5.5 Million and Engagement of Atrium Research
